Date: 2017-07-27
Type of information: Company acquisition
Acquired company: Mapi Group (France)
Acquiring company: Icon (Ireland)
Amount: undisclosed
Terms:
- • On July 2017, Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced that it has acquired the Mapi Group, a leading Patient-Centered Health Outcomes Research and Commercialisation company.
Details:
- The acquisition strengthens Icon’s existing commercialisation and outcomes research business adding significant commercialisation presence, analytics, real world evidence generation and strategic regulatory expertise. The combined organisation will be a leader for real world evidence, post approval research, language services, consultancy services supporting clinical outcomes assessments, pricing and market access and scientific communications.
- The acquisition also enables Icon to have direct access to Mapi Research Trust, the industry’s most subscribed library of Clinical Outcomes Assessments (COAs), with exclusive distribution of over 300 families of validated questionnaires, including licensing of COA services used by commercial, academic and regulatory research organisations. Mapi Group has over 40 years of experience supporting Life-Science companies as the world leading Patient-Centered Research company in commercializing novel treatments through Real-World Evidence, Strategic Regulatory Services, Pharmacovigilance, Market Access, Language Services.
Related: CRO
Is general: Yes
